- Home
- JHI vs NVCT Comparison
JHI vs NVCT Comparison
Compare JHI & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- NVCT
- Stock Information
- Founded
- JHI 1971
- NVCT 2020
- Country
- JHI United States
- NVCT United States
- Employees
- JHI N/A
- NVCT N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- JHI Finance
- NVCT Health Care
- Exchange
- JHI Nasdaq
- NVCT Nasdaq
- Market Cap
- JHI 121.0M
- NVCT 117.3M
- IPO Year
- JHI N/A
- NVCT 2022
- Fundamental
- Price
- JHI $14.36
- NVCT $6.08
- Analyst Decision
- JHI
- NVCT Strong Buy
- Analyst Count
- JHI 0
- NVCT 1
- Target Price
- JHI N/A
- NVCT $21.00
- AVG Volume (30 Days)
- JHI 29.5K
- NVCT 90.8K
- Earning Date
- JHI 01-01-0001
- NVCT 11-06-2024
- Dividend Yield
- JHI 6.80%
- NVCT N/A
- EPS Growth
- JHI N/A
- NVCT N/A
- EPS
- JHI 1.05
- NVCT N/A
- Revenue
- JHI N/A
- NVCT N/A
- Revenue This Year
- JHI N/A
- NVCT N/A
- Revenue Next Year
- JHI N/A
- NVCT N/A
- P/E Ratio
- JHI $12.47
- NVCT N/A
- Revenue Growth
- JHI N/A
- NVCT N/A
- 52 Week Low
- JHI $11.63
- NVCT $5.85
- 52 Week High
- JHI $13.40
- NVCT $12.10
- Technical
- Relative Strength Index (RSI)
- JHI 81.13
- NVCT 40.97
- Support Level
- JHI $13.73
- NVCT $5.90
- Resistance Level
- JHI $14.15
- NVCT $6.38
- Average True Range (ATR)
- JHI 0.10
- NVCT 0.37
- MACD
- JHI 0.03
- NVCT -0.03
- Stochastic Oscillator
- JHI 83.56
- NVCT 17.71
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.